On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine SpikevaxTM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.

Moderna assumed responsibility for all Spikevax™ activities, including import, local regulatory, development, quality assurance, and commercialization. Takeda continued to provide distribution support under the current national vaccination campaign for Moderna COVID-19 vaccines for a transitional period. Both companies were responsible for ensuring proper implementation of operations associated with this transfer.